The notification fixes the maximum retail price at which these formulations can be sold, excluding GST, and manufacturers will not be allowed to sell them above the notified rates.Major formulations include empagliflozin-sitagliptin-metformin tablets priced at Rs 14.88 per tablet, sitagliptin-glimepiride-metformin tablets priced at Rs 11.91 per tablet, teneligliptin-dapagliflozin tablets priced at Rs 10.17 per tablet and atorvastatin-fenofibrate tablets priced at Rs 18.46 per tablet. Tacrolimus capsules, used by organ transplant patients, have been priced at Rs 127 per capsule.The list also includes Vitamin D3 oral solution, calcium and vitamin supplements, cefpodoxime-clavulanate antibiotic suspension for children and norethisterone acetate tablets for women’s health.Industry representatives said the notified prices of many commonly used drugs are lower than the prevailing market rates. However, market prices may vary according to different brands and strengths. All India Organization of Chemists and Druggists general secretary Rajeev Singhal welcomed the move and said consumers are likely to benefit from the revised prices in 60-90 days, once the existing stock in the supply chain is cleared and the revised-MRP stock reaches the market.Health experts say the contribution of medicines to household health care expenditure in India is significant, especially for patients suffering from chronic conditions like diabetes, hypertension and heart disease. Affordable access to treatment is considered important for reducing the financial burden on families and improving adherence to long-term therapy.